Why the study?
Do angiotensin converting enzyme (ACE) inhibitors improve mortality and quality of life in patients with heart failure with reduced ejection fraction?
Do angiotensin converting enzyme (ACE) inhibitors improve mortality and quality of life in patients with heart failure with reduced ejection fraction?
ACE inhibitors provide significant benefits in mortality, hospital admissions, and quality of life for patients with HFrEF, though clinicians must be mindful of contraindications and drug interactions.
Answers are grounded in this paper and cite their sources.
Supports ACE inhibitor benefits in HFrEF; leaves open nurse prescriber implementation and training needs.
Heart failure with reduced ejection fraction is associated with increased mortality and reduced quality of life. In episodes of acute decompensation, compensatory mechanisms such as the sympathetic nervous system and the renin-angiotensin-aldosterone system attempt to maintain peripheral perfusion but also increase the workload of a failing left ventricle. Treatment with angiotensin converting enzyme (ACE) inhibitors has reduced mortality, reduced frequency of hospital admissions and improved quality of life. Despite benefits in mortality reduction and improved quality of life, several contraindications exist, such as bilateral renal artery stenosis. In addition, there is potential for drug to drug interactions potentiating the risk for symptomatic hypotension.
No takes yet. Share an insight, caveat, or question.
Kate O’Donovan (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: